Executive · Operator
Paul Blanchfield
Paul Blanchfield is the CEO of Alpha-9 Oncology, a Boston-based clinical-stage radiopharmaceutical company developing targeted alpha and beta therapies for cancer. He took the top job in November 2025 after running Lantheus as President, following earlier operator stints at Takeda and Shire and a five-year run at McKinsey.